Answers are grounded in this paper and cite their sources.
Background Abemaciclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved for breast cancer. The CDK4/6 pathway is essential for cell cycle progression. Pediatric cancers often harbor aberrations in this pathway, potentially rendering sensitivity to CDK4/6 inhibition. Procedure In this multicenter, open-label, phase 1 trial (JPCS; NCT04238819), children and young adults with relapsed/refractory solid tumors were nonrandomly assigned to standard-dose irinotecan and temozolomide with abemaciclib in a 3 + 3 escalation design with 4 planned dose levels (55, 70 [starting dose], 90, and 115 mg/m 2 twice daily [BID]). An expansion phase followed. The primary objective was recommended phase 2 dose (RP2D) determination for abemaciclib based on safety and pharmacokinetics. A secondary endpoint was antitumor activity. Results Twenty patients enrolled (median age: 12 [7−17] years) with central nervous system tumors as the most frequent diagnosis. The abemaciclib RP2D was 55 mg/m 2 BID. One of 12 dose-limiting toxicity (DLT)-evaluable patients experienced a DLT (thrombocytopenia) at the RP2D. At the RP2D, the most frequent treatment-related adverse events (TRAEs) were diarrhea (92 %), neutropenia (77 %), thrombocytopenia (62 %), and anemia (62 %), and the most common grade 3/4 TRAEs were neutropenia (62 %), thrombocytopenia, leukopenia, and anemia (each 31 %). At the RP2D, patients received a median of 4 (2−35) cycles of abemaciclib, and best overall response included 1 (5 %) complete response and 6 (46 %) stable disease. Abemaciclib plasma concentrations were within the range associated with efficacy in adults. Conclusions Abemaciclib 55 mg/m 2 BID with irinotecan and temozolomide was tolerable and showed potential antitumor activity in children and young adults with relapsed/refractory malignant solid tumors.
No takes yet. Share an insight, caveat, or question.
Ribelles et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: